Amid Dwindling Quarterly Sales, Sema4 Announces More Layoffs

  • Sema4 Holdings Corp SMFR reported Q2 revenues of $36.2 million compared to $47.0 million a year ago.
  • Testing volumes on a reported basis were up 63% Y/Y, with 117,838 tests resulting (excluding COVID-19 tests).
  • Sema4 reported a Q4 Basic EPS loss of $(0.25). The company held $285 million in cash and equivalents.
  • Restructuring: The company is on track to deliver its previously announced cost savings target of approximately $50 million in 2022. 
  • With additional initiatives underway, the company will be on target to achieve over $150 million in annualized savings and approximately $200 million in cumulative savings by the end of 2023.
  • Sema4 eliminated approximately 250 positions, representing approximately 13% of its workforce, and exited the somatic tumor testing business.
  • Guidance: Sema4 expects FY22 revenues of $245-$255 million, below the consensus of $305.6 million and previous guidance of $305-$315 million.
  • The guidance includes a $24 million reduction in revenue due to the estimated change and a more conservative outlook on volumes and pricing trends within reproductive health product lines.
  • The company expects an adjusted gross margin of 4-9%, far below over 20% expected earlier.
  • Price Action: SMFR shares traded 28.5% lower at $1.72 on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Posted In: EarningsNewsPenny StocksGuidanceHealth CareSmall CapMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!